Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sagimet Biosciences Inc. (SGMT : NSDQ)

• Company Description    Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $9.91 Daily Weekly Monthly 20 Day Moving Average: 1,508,852 shares Shares Outstanding: 30.67 (millions) Market Capitalization: $303.99 (millions) Beta: 3.35 52 Week High: $10.43 52 Week Low: $1.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 15.10% 10.79% 12 Week 348.42% 277.18% Year To Date 120.22% 106.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 155 BOVET RD. SUITE 303 - SAN MATEO,CA 94402 USA ph: 650-561-8600 fax: - ir@sagimet.com http://www.sagimet.com

• General Corporate Information    Officers David Happel - President and Chief Executive Officer George Kemble - Executive Charmain Thierry Chauche - Chief Financial Officer Anne Phillips - Director Beth Seidenberg - Director Peer Information Sagimet Biosciences Inc. (CORR.) Sagimet Biosciences Inc. (RSPI) Sagimet Biosciences Inc. (CGXP) Sagimet Biosciences Inc. (BGEN) Sagimet Biosciences Inc. (GTBP) Sagimet Biosciences Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 786700104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 30.67 Most Recent Split Date: (:1) Beta: 3.35 Market Capitalization: $303.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.19 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -143.48% vs. Previous Quarter: -12.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -35.21 12/31/24 - -26.05 ROA 06/30/25 - - 03/31/25 - -34.09 12/31/24 - -25.36 Current Ratio 06/30/25 - - 03/31/25 - 20.34 12/31/24 - 34.30 Quick Ratio 06/30/25 - - 03/31/25 - 20.34 12/31/24 - 34.30 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 4.53 12/31/24 - 5.08 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©